Eliyazar Gaddam, MD
Cardiovascular Disease · Lima, OHNPI 1073561858
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,612 of the $2,677 with a category attached, or 60.2%. 7 manufacturers reported payments, led by Amgen at 57.3% of the total. 2025 is the largest year on record at $1,599, more than ten times the $38 reported in 2019.
Across 45 payments — averaging $59.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
- Merck$42
- GSK$37
- Edwards Lifesciences$32
- Angiodynamics, Inc.$15
- plus $14 from 1 others
Across 91 payments — averaging $5673.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$205K
- AstraZeneca$100K
- Amgen$70K
- Kiniksa Pharmaceuticals, Ltd.$70K
- GSK$63K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$8K
What the payments were for
- Travel & lodging$1,06540%
- Food & beverage$1,61260%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 6 | $1,535 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 31 | $1,001 |
| Merck | 3 | $42 |
| GSK | 2 | $37 |
| Edwards Lifesciences | 1 | $32 |
| Angiodynamics, Inc. | 1 | $15 |
| Avion Pharmaceuticals | 1 | $14 |
How this compares
$2,677 in reported general payments places this provider in the 60th percentile of 827 cardiovascular disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mesalamine ErMesalamine | 11 | $1,880 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 19 | $711 |
| Nifedipine ErNifedipine | 28 | $439 |
| Enalapril Maleate | 34 | $409 |
| Atorvastatin Calcium | 32 | $230 |
| Metoprolol Succinate | 18 | $225 |
| Levothyroxine Sodium | 13 | $200 |
| Carvedilol | 14 | $124 |
| Mycophenolate Mofetil | 11 | $104 |
| Amlodipine Besylate | 23 | $103 |
| Losartan Potassium | 12 | $78 |
| Furosemide | 31 | $68 |
| Tamsulosin Hcl | 12 | $58 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 11 | $35 |
| Potassium Chloride | 11 | $27 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Lima
- Sandeep PatelLima$152K
- Guilherme AttizzaniCleveland$1.3M
- Gregory LamCircleville$428K
- Emil HayekHudson$379K
- Abraham LincoffCleveland$369K
- Oussama WazniCleveland$367K
- Ian NeelandCleveland$329K
- Kamal ShemisaCincinnati$314K
- Mehdi ShishehborElyria$237K
- Abdu HawwaGarfield Hts$234K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.